(Q38002654)

English

Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease

scientific article published on 06 April 2012

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Simultaneous analysis of cerebrospinal fluid biomarkers using microsphere-based xMAP multiplex technology for early detection of Alzheimer's disease (English)

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

0 references

Alzheimer's disease

0 references

cerebrospinal fluid

0 references

1 reference

based on heuristic

inferred from title

John Q. Trojanowski

3

object named as

John Q Trojanowski

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

4

object named as

Leslie M Shaw

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Hugo Vanderstichele

2

object named as

Hugo Vanderstichele

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

author name string

Ju-Hee Kang

1

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

publication date

6 April 2012

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

56

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

4

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

484-493

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

CSF Abeta 42 levels correlate with amyloid-neuropathology in a population-based autopsy study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Relationships between biomarkers in aging and dementia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Cerebrospinal fluid {beta}-amyloid 42 and tau proteins as biomarkers of Alzheimer-type pathologic changes in the brain.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

The amyloid hypothesis of Alzheimer's disease: progress and problems on the road to therapeutics

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Hypothetical model of dynamic biomarkers of the Alzheimer's pathological cascade

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Cerebrospinal fluid and plasma biomarkers in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

A century of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Stages of the pathologic process in Alzheimer disease: age categories from 1 to 100 years.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Practice parameter: diagnosis of dementia (an evidence-based review). Report of the Quality Standards Subcommittee of the American Academy of Neurology

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Modeling the association between 43 different clinical and pathological variables and the severity of cognitive impairment in a large autopsy cohort of elderly persons

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Preclinical AD Workgroup staging: pathological correlates and potential challenges.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Transient increase in total tau but not phospho-tau in human cerebrospinal fluid after acute stroke.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Initial CSF total tau correlates with 1-year outcome in patients with traumatic brain injury.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

PET imaging of amyloid deposition in patients with mild cognitive impairment.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Can CSF biomarkers or pre-treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease?

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Cerebrospinal fluid total tau as a marker of Alzheimer's disease intensity.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Correlation of cerebrospinal fluid levels of tau protein phosphorylated at threonine 231 with rates of hippocampal atrophy in Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Total and phosphorylated tau protein as biological markers of Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Biological markers of amyloid beta-related mechanisms in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Association between CSF biomarkers and incipient Alzheimer's disease in patients with mild cognitive impairment: a follow-up study

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of Department of Health and Human Services Task Force on Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Lewy Body Pathology in Alzheimer's Disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Diagnostic accuracy of Alzheimer's disease: a clinicopathological study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

The neuropathology of probable Alzheimer disease and mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Alzheimer's disease: clinical trials and drug development

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Consensus Report of the Working Group on: “Molecular and Biochemical Markers of Alzheimer’s Disease” 11The names of the Working Group Members and the names of the Working Group Advisory Committee Members are listed in the Appendix A(section VI)

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Improved discrimination of AD patients using beta-amyloid(1-42) and tau levels in CSF.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Decreased beta-amyloid1-42 and increased tau levels in cerebrospinal fluid of patients with Alzheimer disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Total and phosphorylated tau proteins: evaluation as core biomarker candidates in frontotemporal dementia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

CSF biomarkers in frontotemporal lobar degeneration with known pathology

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Biomarkers for early detection of Alzheimer pathology

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Simultaneous measurement of beta-amyloid(1-42), total tau, and phosphorylated tau (Thr181) in cerebrospinal fluid by the xMAP technology.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Diagnostic accuracy of ELISA and xMAP technology for analysis of amyloid beta(42) and tau proteins.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Amino-truncated beta-amyloid42 peptides in cerebrospinal fluid and prediction of progression of mild cognitive impairment

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

DJ-1 and alpha-synuclein in human cerebrospinal fluid as biomarkers of Parkinson's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

A fluorescent microsphere-based method for assay of multiple analytes in plasma.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Hormones as biomarkers: practical guide to utilizing luminex technologies for biomarker research

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Use of Luminex xMAP-derived Bio-Plex bead-based suspension array for specific detection of PPV W and characterization of epitopes on the coat protein of the virus.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Qualification of the analytical and clinical performance of CSF biomarker analyses in ADNI.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Measurement of Aβ1-42 in cerebrospinal fluid is influenced by matrix effects.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Cerebrospinal fluid tau and beta-amyloid 42 proteins identify Alzheimer disease in subjects with mild cognitive impairment.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Cerebrospinal fluid levels of β-amyloid 1-42, but not of tau, are fully changed already 5 to 10 years before the onset of Alzheimer dementia

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Biochemical diagnosis of Alzheimer disease by measuring the cerebrospinal fluid ratio of phosphorylated tau protein to beta-amyloid peptide42.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Prevalence and prognostic value of CSF markers of Alzheimer's disease pathology in patients with subjective cognitive impairment or mild cognitive impairment in the DESCRIPA study: a prospective cohort study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Diagnosis-independent Alzheimer disease biomarker signature in cognitively normal elderly people

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

The Alzheimer's Association external quality control program for cerebrospinal fluid biomarkers

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Effect of Sample Collection Tubes on Cerebrospinal Fluid Concentrations of Tau Proteins and Amyloid Peptides

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

The impact of decreased bead count to determine concentrations of amyloid beta1-42, total-tau, and phosphorylated-tau181 in human cerebrospinal fluid using xMAP technology

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Fluctuations of CSF amyloid-beta levels: implications for a diagnostic and therapeutic biomarker.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Standardization of preanalytical aspects of cerebrospinal fluid biomarker testing for Alzheimer's disease diagnosis: a consensus paper from the Alzheimer's Biomarkers Standardization Initiative

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Nonspecific binding of Aβ42 to polypropylene tubes and the effect of Tween-20

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Effects of processing and storage conditions on amyloid beta (1-42) and tau concentrations in cerebrospinal fluid: implications for use in clinical practice.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

The impact of blood contamination on the proteome of cerebrospinal fluid

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Preanalytical Sample Handling and Sample Stability Testing for the Neurochemical Dementia Diagnostics

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Recommendations for the bioanalytical method validation of ligand-binding assays to support pharmacokinetic assessments of macromolecules

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Fit-for-purpose method development and validation for successful biomarker measurement.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

International quality control survey of neurochemical dementia diagnostics.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

A worldwide multicentre comparison of assays for cerebrospinal fluid biomarkers in Alzheimer's disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Multiplexed quantification of dementia biomarkers in the CSF of patients with early dementias and MCI: a multicenter study.

1 reference

https://api.crossref.org/works/10.1016%2FJ.YMETH.2012.03.023

7 January 2021

Identifiers

10.1016/J.YMETH.2012.03.023

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

26 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38002654&oldid=1736904116"